Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when 4D Molecular Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get FDMT alerts

About David Kirn, M.D.

David Kirn, M.D. is recorded as CEO at 4D Molecular Therapeutics, Inc. (FDMT) since January 1, 2026. 4D Molecular Therapeutics, Inc. reported in an 8-K filed January 7, 2026 that David Kirn, M.D. was appointed President and Chief Executive Officer, effective January 1, 2026. 4D Molecular Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at 4D Molecular Therapeutics, Inc. includes David Kirn (CEO and Board Member), Ashoo Gupta (CFO), Kristian Humer (CFO and Chief Accounting Officer) and 7 others.

“Effective January 1, 2026, following the resignation of Dr. Kamal as President, the Board of Directors of the Company (the "Board") appointed David Kirn, M.D., the Company's current Chief Executive Officer, as the President and Chief Executive Officer of the Company.”
4D Molecular Therapeutics, Inc. Form 8-K, filed January 7, 2026 · Read the filing

Affiliation history

Company network

Leadership on record at 4D Molecular Therapeutics, Inc.

Recent activity